Presentation

Genovis offers pharmaceutical and medical device industries tools that facilitate the development of new treatments and diagnostics. The unique portfolio of reagents and technologies offered by the Genovis Group is used by industry-leading and global pharmaceutical companies in research, analytical characterisation, process development and quality control. Two product portfolios can be found within the Genovis Group: SmartEnzymes and Antibodies & Services, including a total of 22 enzymes in different product formats under the SmartEnzymes™ brand.

Recent highlights
In Q2, net sales totaled SEK 21.1M (+52%) with 37% growth, adjusted for currency effects.
In October 2021, Genovis announced exclusive license agreement with Selecta Bioscience to develop and promote a novel IgG Protease in Gene Therapy and Autoimmune Disease. In August 2022, Genovis entered service agreement with evitria AG to offer evitria’s customers fast LC-MS characterization of recombinant antibodies using Genovis proprietary enzyme. Also in the same month, Genovis signed a long-term licensing and supply agreement with a US based biotech company for the supply of SmartEnzymesTM to be used in the manufacturing of a clinical therapeutic agent.

Outlook
Toward the end of Q2, the company experienced certain challenges in the supply of raw materials for parts of the product range, which may have a temporary effect on its ability to deliver in the future. Although geopolitical factors around the world remain uncertain, the company’s assessment is that the situation should be able to normalise in the third quarter. The beginning of Q3 shows customer activity and growth.